Stenting and glycoprotein IIb/IIIa inhibition in patients with acute myocardial infarction undergoing percutaneous coronary intervention: Findings from the global registry of acute coronary events (GRACE)

Autor: Frederick A. Spencer, Kami White, Brian M. Kennelly, Dietrich C. Gulba, Joel M. Gore, Frans Van de Werf, Gilles Montalescot, Alvaro Avezum, David Brieger, Tomasz Mazurek
Rok vydání: 2003
Předmět:
Adult
Male
medicine.medical_specialty
Time Factors
medicine.medical_treatment
Myocardial Infarction
Coronary Disease
Platelet Glycoprotein GPIIb-IIIa Complex
Blood Vessel Prosthesis Implantation
Postoperative Complications
Fibrinolytic Agents
Risk Factors
Internal medicine
Angioplasty
medicine
Humans
Radiology
Nuclear Medicine and imaging
Hospital Mortality
Registries
cardiovascular diseases
Myocardial infarction
Angioplasty
Balloon
Coronary
Coronary Artery Bypass
Aged
Chemotherapy
business.industry
Incidence
Australia
Percutaneous coronary intervention
Stent
General Medicine
Middle Aged
equipment and supplies
medicine.disease
Combined Modality Therapy
Europe
Treatment Outcome
surgical procedures
operative
Multivariate Analysis
Conventional PCI
Cardiology
Female
Stents
Americas
Cardiology and Cardiovascular Medicine
Glycoprotein IIb/IIIa
business
Fibrinolytic agent
New Zealand
Zdroj: Catheterization and Cardiovascular Interventions. 60:360-367
ISSN: 1522-726X
1522-1946
DOI: 10.1002/ccd.10653
Popis: Stenting and GP IIb/IIIa inhibition are promising adjunctive therapies in PCI. The Global Registry of Acute Coronary Events (GRACE) is a registry of unselected patients with acute coronary syndromes, allowing for the study of treatments in a real-world environment. Data from GRACE patients with AMI who underwent PCI were analyzed. After adjusting for demographics, baseline characteristics, and previous medications, treatment with GP IIb/IIIa inhibitors and a stent and treatment with a stent alone were significant predictors of survival at 6 months. Stents were used in 90.9% of patients. GP IIb/IIIa inhibitors were used in 59.7%; in most cases they were started after the beginning of the procedure. The in-hospital death rate (7.6%) was highest in patients undergoing urgent PCI. Mortality at 6 months following PCI was 14.4% among patients who received neither GP IIb/IIIa inhibitors nor a stent, compared to patients who received both GP IIb/IIIa inhibitors and a stent (7.3%), GP IIb/IIIa inhibitors alone (12.8%), or a stent alone (6.7%).
Databáze: OpenAIRE
Externí odkaz: